4 Key Insights for Pharma and Healthcare from Davos 2024
Every year, the world’s top business and political leaders converge on the ski village of Davos, Switzerland for the World Economic Forum meeting. Read on for some of the key…
Company Profile
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Switzerland AG
Zählerweg 6
CH 6300 Zug
Switzerland
Phone: +41 41 728 7444
Fax: +41 41 728 7440
www.biogenidec.ch
International Headquarters
Biogen Idec International GmbH
Landis & Gyr-Strasse 3
CH 6300 Zug
Switzerland
Phone: +41 41 39 21700
Fax: +41 41 39 21710
www.biogenidec-international.com
Every year, the world’s top business and political leaders converge on the ski village of Davos, Switzerland for the World Economic Forum meeting. Read on for some of the key…
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…
Ahead of the 78th session of the United Nations General Assembly (UNGA78), IFPMA Director General Thomas Cueni underscores the need for pandemic preparedness plans to support innovation and equity. Global…
Regular contributor Brendan Shaw* casts his eye over the recently announced 2023 WHO Essential Medicines List, how it reflects growing pharmaceutical innovation, and why maintaining a ‘seat at the table’…
Following the appointment of new boards at the US innovative pharma industry body PhRMA, and its European counterpart EFPIA, it is global group the IFPMA’s turn to reveal a new…
At this year’s Swiss Biotech Day, the Swiss Biotech Association celebrated its 25 years of existence and proved the ability of the sector to weather geopolitical disruptions and funding challenges…
Brendan Shaw examines the protracted efforts of global stakeholders to come together around a global pandemic treaty and outlines the benefits of constructive engagement on the part of the pharmaceutical…
Global biopharma is increasingly moving towards biologic medicines, which promise a greater impact on patient’s lives than the small-molecule drugs that preceded them, but which come with significant added costs…
Writing in the June 2023 edition of DIA’s Global Forum magazine, Angelika Joos of MSD and Susanne Ausborn Roche consider some of the key takeaways from a workshop on regulatory…
Takeda’s Mwana Lugogo and Pfizer’s Rady Johnson, the current and former chairs of the IFPMA Ethics & Business Integrity Committee and Chief Ethics & Compliance Officers Roundtable respectively, highlight the…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
IFPMA Director General Thomas Cueni highlights the global innovative pharmaceutical industry’s five key priorities for ensuring better national and international healthcare responses to future pandemics, drawing on the lessons of…
See our Cookie Privacy Policy Here
